Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$32.6K Hold
229
– – 0.02% 292
2026
Q2
$35.9K Hold
229
– – 0.03% 279
2026
Q1
$35K Buy
229
+54
+31% +$8.28K 0.03% 275
2025
Q4
$24.1K Buy
+175
New +$22.9K 0.02% 305

Other funds holding NVS

Bayban's NVS Position: Q3 2026 in Review

Bayban held its Novartis (NVS) position steady in Q3 2026 at 229 shares worth $32.6K. The position accounts for 0.02% of the portfolio, ranked #292.

Bayban first reported a position in NVS in Q4 2025 and has held it in 4 quarters since. The position peaked at $35.9K in Q2 2026. 1,560 funds tracked by Wall St. Rank hold NVS as of Q3 2026.

  • Bayban held 229 shares of Novartis worth $32.6K as of Q3 2026.
  • Bayban left its Novartis share count unchanged in Q3 2026.
  • Novartis made up 0.02% of Bayban's portfolio in Q3 2026, its #292 holding.
  • Bayban first reported a position in Novartis in Q4 2025 and has held it in 4 quarters since.
  • Bayban's Novartis position peaked at $35.9K in Q2 2026.
  • 1,560 funds tracked by Wall St. Rank held Novartis as of Q3 2026.

Based on Bayban's 13F filing for Q3 2026, filed 5 Nov 2026.